RETISERT
`®
`
` VISUDYNE
`®
`
`Important Safety Information Full Prescribing Information
`
`ADDITIONAL PRODUCTS
`
` BAUSCH + LOMB SURGICAL SITE
`
`
`
`FOR PATIENTS
`
`About VISUDYNE
`®
`
`
`
`Efficacy & Safety
`
` Ordering & Patient Assistance
`
`Additional Resources
`
`HELP YOUR PATIENTS OBTAIN
`ACCESS TO VISUDYNE *
`®
`
`Ordering made easy:
`
`CALL
`Besse Medical 1 (888) 767-7123 to order VISUDYNE
`®
`
`CONFIRM
`that you have an existing account
`
`PLACE
`an order and it will be shipped the next day
`
`First-time prescribers of
`VISUDYNE can register
`®
`with Besse Medical by
`signing up for an account
`
`CREATE ACCOUNT
`
`Patient assistance program*
`
`Printable resources for your patients:
`
`ENROLLMENT FORM
`Download the
` savings program
`enrollment form for your patients
`
`FOA CARD
`Print
` information card for
`your patients
`
`FOCUS ON ACCESS (FOA) helps
`™
`eligible patients secure access to
`VISUDYNE and offers the following
`®
`services*:
`
`• Reimbursement information on insurance coverage
`availability for VISUDYNE *
`®
`
`• Patient assistance for eligible patients without
`nsurance coverage or f the product s not covered by
`their insurance plan*
`
`*Terms and conditions apply and can be found on the FOA enrollment form
`Please be sure to share eligibility criteria with your patients Bausch + Lomb
`does not guarantee coverage or reimbursement for the product
`
`For information on reimbursement and patient assistance services
`Call the FOCUS ON ACCESS Hotline: 1 (866) 272-8838
`™
`(Monday-Friday, 9 AM to 5 PM EST)
`
`Indication
`
`Resources are available for your patients
`
`VI UDYNE (verteporf n for nject on) therapy s nd cated for the treatment of pat ents w th predom nantly class c
`®
`subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed
`ocular histoplasmosis.
`
`Important Safety Information
`VISUDYNE (verteporfin for injection) is contraindicated for patients with porphyria or known
`®
`hypersensitivity to any component of this preparation.
`
`Standard precautions should be taken during infusion of VISUDYNE to avoid extravasation,
`®
`including but not limited to:
`
`Exhibit 2159
`Page 01 of 02
`
`

`

`A free-flowing intravenous (IV) line should be established before starting VISUDYNE infusion
`®
`and the line should be carefully monitored.
`
`Due to the possibly fragility of vein walls of some elderly patients, it is strongly recommended
`that the largest arm vein possible preferably the antecubital be used for injection
`
`Small veins in the back of the hand should be avoided.
`
`Extravasation of VISUDYNE , especially if the affected area is exposed to light, can cause severe
`®
`pain, inflammation, swelling or discoloration at the injection site. If extravasation does occur, the
`infusion should be stopped immediately The extravasation area must be thoroughly protected from
`direct light until swelling and discoloration have faded in order to prevent the occurrence of local
`burn, which could be severe. Cold compresses should be applied to the injection site. Oral
`medication for pain relief may be administered.
`
`Following injection with VISUDYNE , care should be taken to avoid exposure of skin or eyes to direct
`®
`sunlight or bright indoor light for 5 days. If emergency surgery is necessary within 48 hours after
`treatment, as much of the internal tissue as possible should be protected from intense light.
`
`Patients who experience severe decrease of vision of 4 lines or more within 1 week after treatment
`should not be retreated, at least until their vision completely recovers to pretreatment levels and
`potential benefits and risks of subsequent treatment are carefully considered by the treating
`physician.
`
`The most frequently reported adverse events (occurring in approximately 10%-30% of patients) were
`injection site reactions (including pain, edema, inflammation, extravasation, rashes, hemorrhage, and
`discoloration), and visual disturbances (including blurred vision, flashes of light, decreased visual
`acuity and visual field defects including scotoma)
`
`Click here for full Prescribing Information for VISUDYNE .
`®
`
`
`
` VISUDYNE [package insert], Bausch & Lomb Incorporated
`
` Legal Notice Pri acy Policy Contact Us
`
`VISUDYNE is a registered trademark of Cheplapharm Arzneimittel GmbH used under license
`Bausch
` Lomb Focus on Access and RETISERT are trademarks of Bausch & Lomb Incorporated or its affiliates
`© 2021 Bausch & Lomb Incorporated or its affiliates VID 0025 USA 21
`
`All information and materials on this site pertain to the US only, unless otherwise indicated
`
`CALIFORNIA RESIDENTS DO NOT SELL MY PERSONAL INFORMATION
`
`Exhibit 2159
`Page 02 of 02
`
`